|
Research Note Directory
Pharmos Corporation
Symbol: PARS
Exchange: NASDAQ
10/01/2003. FDA Gives Pharmos Corporationís Lead Product Fast Track Status; Raising Target Price to $3 From $2.50
(PDF Version)
08/13/2003. Pharmos Reports Second Quarter 2003 Results, Progress In Clinical Trials
(PDF Version)
07/02/2003. Pharmos: First US Patient for Phase III Traumatic Brain Injury Trial Enrolled
(PDF Version)
06/12/2003. Pharmos Receives Notice of Allowance for US Patent on Dexanabinol
(PDF Version)
03/13/2003. Pharmos Year End Financial Results And Update on Clinical Trial Status
(PDF Version)
Disclaimer
|